NYSE:PENMedical Equipment
Penumbra (PEN) Wins Early THUNDERBOLT Use, Is The 12% Discount Below Fair Value Enough?
Penumbra (PEN) is back on investor radar after Novant Health reported successful clinical use of its newly cleared THUNDERBOLT computer assisted vacuum thrombectomy system for ischemic stroke treatment in North Carolina.
See our latest analysis for Penumbra.
Penumbra's recent THUNDERBOLT update comes as the stock trades at US$319.49, with a 1 year total shareholder return of 38.81%, while the 3 year total shareholder return of 5.32% and 5 year total shareholder return of 20.43% point to more...